Результаты поиска - Andrew Weickhardt

  • Отображение 1 - 20 результаты of 20
Отмена результатов
  1. 1
    Oxaliplatin-Induced Neuropathy in Colorectal Cancer

    Oxaliplatin-Induced Neuropathy in Colorectal Cancer по Andrew Weickhardt, Keith Wells, Wells A. Messersmith

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Radiotherapy and immunotherapy: a synergistic effect in cancer care

    Radiotherapy and immunotherapy: a synergistic effect in cancer care по Guy‐Anne Turgeon, Andrew Weickhardt, Arun Azad, Benjamin Solomon, Shankar Siva

    Опубликовано 2018
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer

    Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer по Andrew Weickhardt, Dara L. Aisner, Wilbur A. Franklin, Marileila Varella‐Garcia, Robert C. Doebele, D. Ross Camidge

    Опубликовано 2012
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

    Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib по Evelyn M. Brosnan, Andrew Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol, D. Ross Camidge

    Опубликовано 2013
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

    Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Pati... по Gregory N. Gan, Andrew Weickhardt, Benjamin Scheier, Robert C. Doebele, Laurie E. Gaspar, Brian D. Kavanagh, D. Ross Camidge

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer

    Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer по Andrew Weickhardt, Micol S. Rothman, Smita Salian‐Mehta, Katja Kiseljak‐Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman, D. Ross Camidge

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

    Impact of <i>KRAS</i> and <i>BRAF</i> Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in... по Timothy Price, Jennifer E. Hardingham, Chee Khoon Lee, Andrew Weickhardt, Amanda Townsend, Joe Wrin, Ann Chua, Aravind Shivasami, Michelle M. Cummins, Carmel Murone, Niall C. Tebbutt

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

    Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer по Andrew Weickhardt, Benjamin Scheier, Joseph Burke, Gregory N. Gan, Xian Lu, Paul A. Bunn, Dara L. Aisner, Laurie E. Gaspar, Brian D. Kavanagh, Robert C. Doebele, D. Ross Camidge

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Prospective, Multisite, International Comparison of <sup>18</sup>F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes

    Prospective, Multisite, International Comparison of <sup>18</sup>F-Fluoromethylcholine PET/CT, Multiparametric MRI, and <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk... по Louise Emmett, Ur Metser, Glenn Bauman, Rodney J. Hicks, Andrew Weickhardt, Ian D. Davis, Shonit Punwani, Gregory R. Pond, Sue Chua, Bao Ho, Edward W. Johnston, Frédéric Pouliot, Andrew M. Scott

    Опубликовано 2018
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer

    Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherap... по Andrew Weickhardt, Timothy Price, Geoff Chong, Val Gebski, Nick Pavlakis, Terrance G. Johns, Arun Azad, Effie Skrinos, Kate Fluck, Alexander Dobrovic, Renato Salemi, Andrew M. Scott, John M. Mariadason, Niall C. Tebbutt

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

    Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer по Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee Maxson, Andrew Weickhardt, Ana B. Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella‐Garcia, D. Ross Camidge

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer

    Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer по Robert C. Doebele, Amanda B. Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew Weickhardt, Kimi Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marileila Varella‐Garcia, D. Ross Camidge

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    <i>ROS1</i> and <i>ALK</i> Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers

    <i>ROS1</i> and <i>ALK</i> Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers по Dara L. Aisner, Teresa T. Nguyen, Diego D’Ávila Paskulin, Anh T. Le, Jerry Haney, Nathan Schulte, Fiona Chionh, Jennifer E. Hardingham, John M. Mariadason, Niall C. Tebbutt, Robert C. Doebele, Andrew Weickhardt, Marileila Varella‐Garcia

    Опубликовано 2013
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

    Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer по Andrew Weickhardt, David S. Williams, Chee Khoon Lee, Fiona Chionh, John Simes, Carmel Murone, Kate Wilson, Michelle Parry, K. Asadi, Andrew M. Scott, Cornelis J.A. Punt, Irıs D. Nagtegaal, Timothy Price, John M. Mariadason, Niall C. Tebbutt

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

    Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients по Andrew Weickhardt, Robert C. Doebele, W. Thomas Purcell, Paul A. Bunn, Ana B. Oton, Micol S. Rothman, Margaret E. Wierman, Tony Mok, Sanjay Popat, Julie E. Bauman, Jorge J. Nieva, Silvia Novello, Sai‐Hong Ignatius Ou, D. Ross Camidge

    Опубликовано 2013
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

    A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cel... по Andrew Weickhardt, Robert C. Doebele, Ana B. Oton, Janice Lettieri, DeLee Maxson, Michele D. Reynolds, Amy Brown, Mary K. Jackson, Grace K. Dy, Araba A. Adjei, Gerald J. Fetterly, Xian Lu, Wilbur A. Franklin, Marileila Varella‐Garcia, Fred R. Hirsch, Murry W. Wynes, Hagop Youssoufian, Alex A. Adjei, D. Ross Camidge

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

    Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial по Charu Aggarwal, Amy Prawira, Scott Antonia, Osama E. Rahma, Anthony W. Tolcher, Roger B. Cohen, Yanyan Lou, Ralph J. Hauke, Nicholas J. Vogelzang, Dan P. Zandberg, Arash Rezazadeh Kalebasty, Victoria Atkinson, Alex A. Adjei, ­Mahesh Seetharam, Ariel E. Birnbaum, Andrew Weickhardt, Vinod Ganju, Anthony M. Joshua, Rosetta Cavallo, Linda Peng, Xiaoyu Zhang, Sanjeev Kaul, Jan Baughman, Ezio Bonvini, Paul A. Moore, S. Goldberg, Fernanda I. Arnaldez, Robert L. Ferris, Nehal J. Lakhani

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

    The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial по Jason J. Luke, Manish R. Patel, George R. Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V. Ulahannan, Roisín M. Connolly, Cesar A. Santa‐Maria, Jie Wang, Shakeela Bahadur, Andrew Weickhardt, Adam S. Asch, Girish Mallesara, Philip R. Clingan, Monika Długosz‐Danecka, Monika Tomaszewska‐Kiecana, Halyna Pylypenko, Nada Hamad, Hedy L. Kindler, Bradley Sumrow, Patrick Kaminker, Francine Z. Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H. Smith, Anushka De Costa, Jonathan Li, Hua Li, Jichao Sun, Paul A. Moore

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies по Chia‐Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martín, Michela Maur, Rina Hui, Ross A. Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel S.W. Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer L. Spratlin, Taito Esaki, Frédéric Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo de Braud

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies по Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín, Maria Ochoa de Olza, John Sarantopoulos, Richard D. Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo de Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauß, Barbara Deschler-Baier, Allen S. Lau, Tanay S. Samant, Tyler A. Longmire, Niladri Roy Chowdhury, Catherine Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L. Kwak, David S. Hong

    Опубликовано 2022
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: